Holowesko Partners Ltd. lifted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 8.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,000 shares of the pharmaceutical company’s stock after purchasing an additional 5,000 shares during the period. GlaxoSmithKline comprises 0.7% of Holowesko Partners Ltd.’s holdings, making the stock its 18th biggest holding. Holowesko Partners Ltd.’s holdings in GlaxoSmithKline were worth $2,588,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in GSK. Reilly Financial Advisors LLC grew its stake in shares of GlaxoSmithKline by 131.7% in the 2nd quarter. Reilly Financial Advisors LLC now owns 695 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 395 shares during the last quarter. Evoke Wealth LLC grew its stake in shares of GlaxoSmithKline by 152.6% in the 1st quarter. Evoke Wealth LLC now owns 730 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 441 shares during the last quarter. RMR Wealth Builders grew its stake in shares of GlaxoSmithKline by 67.1% in the 1st quarter. RMR Wealth Builders now owns 752 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 302 shares during the last quarter. SRS Capital Advisors Inc. acquired a new position in shares of GlaxoSmithKline in the 2nd quarter worth approximately $33,000. Finally, Capital Analysts LLC acquired a new position in shares of GlaxoSmithKline in the 2nd quarter worth approximately $35,000. 12.25% of the stock is currently owned by institutional investors.
Shares of GSK opened at $38.85 on Tuesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.53 and a current ratio of 0.82. The company has a market capitalization of $104.61 billion, a PE ratio of 16.39, a PEG ratio of 2.10 and a beta of 0.70. The company’s 50 day moving average price is $40.45 and its 200 day moving average price is $38.90. GlaxoSmithKline plc has a 52 week low of $33.26 and a 52 week high of $42.68.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 7th. Shareholders of record on Friday, August 20th will be paid a $0.523 dividend. This represents a $2.09 dividend on an annualized basis and a yield of 5.38%. The ex-dividend date of this dividend is Thursday, August 19th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 70.13%.
Several research analysts have recently weighed in on GSK shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, August 20th. Barclays reissued an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, July 19th. Baader Bank reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, June 2nd. Morgan Stanley reissued an “equal weight” rating on shares of GlaxoSmithKline in a research report on Tuesday, July 6th. Finally, UBS Group reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, GlaxoSmithKline has a consensus rating of “Hold” and a consensus price target of $41.00.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
Read More: Inflation
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.